Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR)

NACompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

September 30, 2014

Conditions
Coronary Artery Disease
Interventions
DRUG

FFR Measurement with IV Adenoscan® then with Regadenoson

Testing will be completed during a Left Heart Catheterization (LHC). The first 48 eligible patients enrolled will receive an initial infusion of IV Adenoscan® through a peripheral vein at 140 mcg/kg/min. FFR measurements will be obtained utilizing a coronary pressure guide wire once peak hyperemia has been achieved. It takes about 84 seconds to reach peak hyperemia with Adenoscan®. Subsequently, these subjects will receive a dose of regadenoson at 0.4 mg through the same peripheral access site. FFR measurements will be obtained once peak hyperemia is achieved, which takes less than 30 seconds with regadenoson. Patients who react to either medication will be supported conservatively under close scrutiny.

Trial Locations (1)

70121

Ochsner Medical Center, New Orleans

Sponsors
All Listed Sponsors
collaborator

Astellas Pharma Global Development, Inc.

INDUSTRY

lead

Ochsner Health System

OTHER